Abstract:Cancer targeting gene-viro-therapy (CTGVT) approach has become a hotspot and a trend in the field of cancer biotherapy and oncolytic adenovirus is an ideal vector to carry the targeting genes. In this study, we used human telomerase reverse transcriptase (hTERT) promoter to control the adenovirus early region 1a (E1A) and the human α-fetoprotein (AFP) promoter integrated with hypoxia response element (HRE) to control the adenovirus early region 1b (E1B). Then the novel double-regulated adenovirus Ad-hTERT-HREAF (named SG505) was engineered. The short-hairpin RNA against focal adhesion kinase (FAK) was inserted into SG505 and thus forming Ad-hTERT-HREAF-shRNA (called SG505‑siFAK). Then various oncolytic adenoviruses were examined to verify whether they could suppress liver cancer cells selectively and efficiently both in vitro and in vivo. Both replicative and replication-defective adenoviruses carrying FAK-shRNA significantly inhibited the expression of FAK in Hep3B and SMMC-7721 cell lines and efficiently suppressed the growth of liver cancer cell lines with minor effect to normal cells. Furthermore, the recombined oncolytic adenoviruses, SG505-siFAK, SG505-EGFP and SG505 were able to selectively propagate in AFP-positive liver cancer cells in vitro and the SG505-siFAK efficiently suppressed the expression of FAK. SG505-siFAK showed the most potent tumor inhibition capability among the three recombined adenovirus with IC50 levels of 0.092±0.009 and 0.424±0.414 pfu/cell in the Hep3B and HepG2 cell line, respectively. Animal experiment further confirmed that SG505-siFAK achieved the most significant tumor inhibition of Hep3B liver cancer xenografted growth by intratumoral injection comparing to the intravenous injection among the three recombined viruses. Immunohistochemical results indicated that FAK expression was downregulated significantly in the tumors treated with SG505-siFAK. The dual-regulated oncolytic adenovirus SG505-siFAK was proven to inhibit the growth of liver cancer cells selectively and efficiently, therefore SG505-siFAK could be a potential agent for future clinical trials of hepatocellular carcinoma.

Tetracycline controlled DT/VEGF system gene therapy mediated by adenovirus vector

Treatment of patient tumor-derived colon cancer xenografts by a TRAIL gene-armed oncolytic adenovirus

Adenovirus-mediated Tissue-Specific Cytosine Deaminase Gene Therapy for Human Hepatocellular Carcinoma with Different AFP Expression Levels.

Killing effect of tetracyclinecontrolled expression of DT/VEGF system on liver cell cancer

Gene-Viral Cancer Therapy Using Dual-Regulated Oncolytic Adenovirus with Antiangiogenesis Gene for Increased Efficacy

[Gene Expression of Tumor Cells Both in Vitro and in Vivo Enhanced by Integrin-Targeting Adenovirus Vector].

Experimental Investigation of Hepatic Arterial Embolism Treatment with Microsphere Encapsulation of Adenovirus with HSV-TK Gene

Homologous Recombination-Based Adenovirus Vector System for Tumor Cell-Specific Gene Delivery

Genetically Modified Adenoviral Vector with the Protein Transduction Domain of Tat Improves Gene Transfer to CAR-deficient Cells

Targeting Tumor Neoangiogenesis via Targeted Adenoviral Vector to Achieve Effective Cancer Gene Therapy for Disseminated Neoplastic Disease

Effective Gene-Viral Therapy For Telomerase-Positive Cancers By Selective Replicative-Competent Adenovirus Combining With Endostatin Gene

653. the Controlled Transgene Expression in Oncolytic Adenoviral Vectors with Major Late Promoter for Therapy of Cancer

Adenovirus-Mediated Combined Anti-Angiogenic and Pro-Apoptotic Gene Therapy Enhances Antitumor Efficacy in Hepatocellular Carcinoma

Conditionally Replicative Adenovirus Vector Carrying Trail Gene For Enhanced Oncolysis Of Human Hepatocellular Carcinoma

Gene Therapy Targeting Hepatocellular Carcinoma by A Dual-Regulated Oncolytic Adenovirus Harboring the Focal Adhesion Kinase Shrna

Optimization of Adenoviral Vectors to Direct Highly Amplified Prostate-Specific Expression for Imaging and Gene Therapy

Gene-viral Vectors: a Promising Way to Target Tumor Cells and Express Anticancer Genes Simultaneously.

Gene Transfection Efficiency and Expression of Regulatory Recombinant Adeno-Associated Virus Gene Transfer through Direct Infection on MCF-7 Cells

Gene Therapy of Murine Liver Cancer by Intratumoral Injection of Recombinant Adenoviral Vector Carrying Murine Flt3 Ligand

Fiber-modified Adenoviral Vector Expressing the Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Gene from the Human Telomerase Reverse Transcriptase Promoter Induces Apoptosis in Human Hepatocellular Carcinoma Cells

A Fiber-Modified Adenovirus Co-Expressing HSV-TK and Coli.NTR Enhances Antitumor Activities in Breast Cancer Cells.